Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amprenavir

J C Adkins1, D Faulds

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|June 9, 1998
PubMed
Summary
This summary is machine-generated.

Amprenavir, an HIV protease inhibitor, effectively reduces viral load and increases CD4+ cell counts in HIV patients. Common side effects include rash, headache, and diarrhea, but efficacy is maintained in combination therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recombinant hepatitis B vaccine: a review of its immunogenicity and protective efficacy against hepatitis B.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Lepirudin: a review of its potential place in the management of thrombotic disorders.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Inhaled salmeterol/fluticasone propionate combination. A pharmacoeconomic review of its use in the management of asthma.

PharmacoEconomics·2001
Same author

Inhaled fluticasone propionate. A pharmacoeconomic review of its use in the management of asthma.

PharmacoEconomics·2001
Same author

Lopinavir.

Drugs·2001
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Virology
  • Immunology

Background:

  • Amprenavir is a protease inhibitor targeting the HIV protease enzyme.
  • Its resistance profile may differ from other protease inhibitors like saquinavir and indinavir.
  • Therapeutic drug monitoring is crucial for optimizing antiviral efficacy.

Purpose of the Study:

  • To evaluate the pharmacokinetic profile and antiviral efficacy of amprenavir in HIV-infected individuals.
  • To assess the impact of amprenavir monotherapy and combination therapy on viral load and CD4+ cell counts.
  • To identify the common adverse events associated with amprenavir treatment.

Main Methods:

  • Pharmacokinetic analysis of amprenavir plasma concentrations post-administration.
  • Clinical evaluation of amprenavir monotherapy in treatment-naive patients.

Related Experiment Videos

  • Assessment of combination therapy with other antiretroviral agents.

    • Main Results:

    • Plasma concentrations of amprenavir exceeded the 50% inhibitory concentration for HIV-1IIIB.
    • Amprenavir monotherapy increased CD4+ cell counts and decreased viral load in treatment-naive patients.
    • Combination therapy demonstrated sustained viral load reduction and CD4+ cell count increase up to 24 weeks.

    Conclusions:

    • Amprenavir exhibits favorable pharmacokinetics and significant antiviral activity in HIV-infected individuals.
    • Combination therapy with amprenavir and other antiretrovirals is effective in managing HIV infection.
    • Rash, headache, and diarrhea are the most frequent adverse events requiring monitoring.